A World First! NTHU Teams Up with MacKay Hospital to Conduct Human Trials with BNCT
23 oct. 2024 13h00 HE
|
NATIONAL TSING HUA UNIVERSITY
Taiwan's NTHU and MacKay Hospital pioneer world-first human trials of BNCT for liver cancer, offering new hope for patients globally.
Liver Cancer Drugs Market Soaring Towards USD 2,332 Million by 2032 | CAGR of 9.3%
15 janv. 2024 07h21 HE
|
Market.Us
New York, Jan. 15, 2024 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Liver Cancer Drugs Market size is expected to be worth around USD 2,332 Million by 2032 from USD...
Liver Cancer Pipeline Insight | Clinical Trial Research Evaluation Report
25 juil. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 25, 2022 (GLOBE NEWSWIRE) -- Liver Cancer Pipeline Insight | Clinical Trial Research Evaluation Report DelveInsight’s liver cancer pipeline report depicts a robust space with...
Global Biological Therapies Outlook for Cancer 2021-2026: Monoclonal Antibodies Segment Expected to Grow to $124.1 billion in 2026 at a CAGR of 12.8% During 2021 to 2026.
04 oct. 2021 10h48 HE
|
Research and Markets
Dublin, Oct. 04, 2021 (GLOBE NEWSWIRE) -- The "Biological Therapies for Cancer: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering. A rise in the...
Global Liver Cancer Therapeutics Markets Report 2020: Historical Data 2015-2018, Base Year of 2019, Estimates for 2020 & Forecasts 2021-2025
19 janv. 2021 07h33 HE
|
Research and Markets
Dublin, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The "Global Liver Cancer Therapeutics Market, by Cancer Type, by Therapy, by Equipment, by Age, by Factors, by Route of Administration, by Distribution...
Global Liver Cancer Treatment Market is Expected to Reach USD 2,186.63 Million by 2025 : Fior Markets
27 août 2019 05h57 HE
|
Fior Markets
New Jersey, NJ, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Rising incidence of liver cancer and growing research activities for developing novel treatments. The global liver cancer treatment market is...